Oral Drug Candidate for theTtreatment of Pneumocystis Pneumonia - Chinese SFDA Grants Immtech Fast Track Status

Immtech Pharmaceuticals, Inc. (Immtech) (Amex: IMM) announced that the State Food and Drug Administration of the People’s Republic of China (SFDA) has granted Immtech’s application Fast Track Status for conducting a Phase III clinical trial with pafuramidine, the Company’s oral drug candidate for the treatment of Pneumocystis pneumonia (PCP). [click link for full article]

More: continued here

Filed under: Infectious Diseases / Bacteria / Viruses on September 28th, 2007